-+ 0.00%
-+ 0.00%
-+ 0.00%

SAB BIO says Phase 1 SAB-142 trial preserves C-peptide in adult type 1 diabetes

PUBT·04/22/2026 11:05:19
Listen to the news
SAB BIO says Phase 1 SAB-142 trial preserves C-peptide in adult type 1 diabetes
  • SAB Biotherapeutics presented additional Phase 1 data for SAB-142 in established autoimmune type 1 diabetes at IDS 2026.
  • Treated participants showed signs of preserved beta-cell function, with most fitting a “super responder” pattern versus baseline.
  • Results also pointed to improved glucose control, not driven by higher insulin use.
  • Mechanistic findings supported SAB-142’s intended immune-modulating effect, reinforcing its positioning as a potential long-term disease-modifying therapy.
  • SAB Biotherapeutics expects topline results from registrational Phase 2b SAFEGUARD trial in 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220700PRIMZONEFULLFEED9694539) on April 22, 2026, and is solely responsible for the information contained therein.